AI assistant
Sending…
Compugen Ltd. — Regulatory Filings 2010
Mar 21, 2011
6734_rns_2011-03-21_743ba4fb-f43c-4e04-9ce8-feb1f0a2f069.htm
Regulatory Filings
Open in viewerOpens in your device viewer
_________ false
C003�������� ��"�2PublicCOMPUGEN LTD.7411Corporation no: 511779639Stock Exchange/Market: ��������606381Pinchas Rosen 72 , Tel Aviv 69512 , ,Tel: 03-7658585 , 03-7658525 Fax: 03-7658555E.mail address: [email protected] of transmission: 21/03/2011 Time of broadcast: 16:17 16:09:58
Reference: 2011-02-086793
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
| Amended report for distorted report sent on date : 21/03/2011 , Whose reference number was: 2011-02-086688 |
| The distortion: Hebrew title should be 20F report for the year 2010 instead of 2011 |
| The distortion cause: Typing error |
| The main amendment: Correction of Hebrew Title |
Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.
| Attached hereto is a report on | 20F ��� ���� 2010 |
submissionpdfisa_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: |
| Date of revision of form structure: 13/03/2011 |
| - - - |
| Name of the Signatory: : Czaczkes Axselbard Dikla , Position of Signatory in the reporting corporation: Chief Financial Officer , Name of Employer Company: . |
| Pinchas Rozen Telephone: 03-7658585 , Facsimile: 03-7658555 , E-mail: [email protected] 2 |
More from Compugen Ltd.
Capital/Financing Update
2026
May 18
Report Publication Announcement
2026
May 18
Earnings Release
2026
May 18
Report Publication Announcement
2026
May 18
Regulatory Filings
2026
May 12
Report Publication Announcement
2026
May 12
Report Publication Announcement
2026
May 4
Report Publication Announcement
2026
May 4
Director's Dealing
2026
Apr 27
Director's Dealing
2026
Apr 27